证 券 代 码 ： 0 0 0 6 6 1 证 券 简 称 ： 长 春 高 新 公 告 编 号 ： 2 0 2 5 - 1 4 9 本次公司控股股东股权结构变更，不会导致其持有公司股份数量和持股比 例发生变化，不会导致公司控股股东及实际控制人发生变化，公司控股股东仍 为超达集团，实际控制人仍为新区国资局。上述控股股东的股权结构变更事项 不会对公司的正常经营活动产生影响。 特此公告 长春高新技术产业（集团）股份有限公司 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于近日收到 控股股东长春超达投资集团有限公司（以下简称"超达集团"）的通知，获悉超 达集团的股权结构发生变更，并已取得了长春市市场监督管理局长春新区分局换 发的《营业执照》。现就有关情况公告如下： 一、控股股东股权结构变更情况 为优化国有企业资源配置，经长春新区国有资产监督管理局（以下简称" 新区国资局"）决定，龙翔投资控股集团有限公司（以下简称"龙翔集团"） 将其持有超达集团100%股权中的19%股权无偿划转至长春新区产业投资集团有限 公司（以下简称"新区产投"）。上述股权结构变更事项已于近日完成上述股 权划转相关的工商变更登记手续。 调 ...

Core Insights - The Biotech Index (970038) closed at 2182.31 points, down 0.94%, with a trading volume of 13.462 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 7 stocks rose while 42 stocks fell, with Xinlitai leading the gainers at 0.83% and Hualan Biological leading the decliners at 5.98% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price at 204.81, and a decline of 0.92% [1] - Changchun High-tech (sz000661) with a weight of 4.87%, latest price at 102.32, and a decline of 0.27% [1] - Shimeiao (sz002252) with a weight of 4.74%, latest price at 6.70, and a decline of 0.30% [1] - Kanglong Chemical (sz300759) with a weight of 4.55%, latest price at 29.16, and a decline of 1.22% [1] - Tigermed (sz300347) with a weight of 4.54%, latest price at 52.37, and a decline of 2.44% [1] - Shenzhen Technology (sz000021) with a weight of 4.16%, latest price at 23.90, and a decline of 1.77% [1] - Muyuan Foods (sz002714) with a weight of 3.62%, latest price at 48.45, and a decline of 0.31% [1] - Lepu Medical (sz300003) with a weight of 3.19%, latest price at 16.11, and a decline of 1.29% [1] - Aimeike (sz300896) with a weight of 3.16%, latest price at 155.51, and an increase of 0.58% [1] - Yuyue Medical (sz002223) with a weight of 3.07%, latest price at 35.28, and a decline of 0.20% [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 1.382 billion yuan from major funds, while retail investors saw a net inflow of 1.358 billion yuan [1] - Notable capital flows include: - Aimeike (sz300896) had a net inflow of 26.5772 million yuan from major funds, but a net outflow from retail investors of 20.4422 million yuan [2] - Changchun High-tech (sz000661) saw a net inflow of 8.8418 million yuan from major funds, with a slight net inflow from retail investors of 186.25 thousand yuan [2] - Other stocks like Furuisi (sz300049) and Yuyue Medical (sz002223) also showed mixed capital flows with significant net outflows from retail investors [2]

Core Points - The Shenzhen State-Owned Enterprises Shareholder Return Index (470064) closed at 2242.6 points, down 0.16% with a trading volume of 19.728 billion yuan and a turnover rate of 0.87% [1] - Among the index constituents, 11 stocks rose while 36 fell, with Shanjin International leading the gainers at 5.08% and Tianjian Group leading the decliners at 6.77% [1] Index Constituents Summary - The top ten constituents of the Shenzhen State-Owned Enterprises Shareholder Return Index include: - BOE Technology Group (sz000725) with a weight of 9.31%, latest price at 3.92 yuan, down 0.25%, and a total market value of 146.662 billion yuan [1] - Hikvision (sz002415) with a weight of 7.97%, latest price at 30.42 yuan, down 1.01%, and a total market value of 278.795 billion yuan [1] - Wuliangye Yibin (sz000858) with a weight of 7.71%, latest price at 68.61 yuan, down 0.39%, and a total market value of 465.366 billion yuan [1] - Luzhou Laojiao (sz000568) with a weight of 6.59%, latest price at 137.14 yuan, down 1.87%, and a total market value of 201.863 billion yuan [1] - XCMG Machinery (sz000425) with a weight of 5.75%, latest price at 10.15 yuan, up 0.40%, and a total market value of 119.293 billion yuan [1] - Changan Automobile (sz000625) with a weight of 3.88%, latest price at 12.08 yuan, down 0.33%, and a total market value of 119.762 billion yuan [1] - Shenwan Hongyuan (sz000166) with a weight of 3.84%, latest price at 5.32 yuan, unchanged, and a total market value of 133.213 billion yuan [1] - Yun Aluminum (sz000807) with a weight of 3.81%, latest price at 24.12 yuan, up 1.77%, and a total market value of 83.647 billion yuan [1] - Yanghe Brewery (sz002304) with a weight of 3.37%, latest price at 68.48 yuan, down 0.74%, and a total market value of 103.161 billion yuan [1] - Tongling Nonferrous Metals (sz000630) with a weight of 3.18%, latest price at 5.12 yuan, up 1.59%, and a total market value of 68.656 billion yuan [1] Capital Flow Analysis - The index constituents experienced a net outflow of 1.488 billion yuan from main funds, while retail investors saw a net inflow of 1.307 billion yuan [1] - The detailed capital flow for selected stocks includes: - Electric Power Investment Energy (002128) with a main fund net inflow of 59.977 million yuan [2] - Tongling Nonferrous Metals (000630) with a main fund net inflow of 23.384 million yuan [2] - Cloud Aluminum (000807) with a retail net inflow of 17.505 million yuan [2]

Core Viewpoint - The company is actively pursuing several strategic initiatives that are expected to enhance its market position and profitability, including the introduction of new products and the divestiture of real estate assets [1] Group 1: Product Development and Market Potential - The company is on the verge of having Jin Nakan (金纳单抗) included in breakthrough therapy designation [1] - Anwo Gao (安沃高新) is set to commence production, with an expected annual output value of 3 billion [1] - The market for insoles and weight loss drugs is substantial, which is anticipated to generate significant profits [1] - The introduction of methylphenidate hydrochloride (盐酸右哌甲酯) is expected to tap into a large market space [1] - Jin Tuoxizhu (金妥昔单抗) and Jin Tuolizhu (金妥利珠单抗) are projected to be billion-dollar products [1] Group 2: Strategic Initiatives and Financial Management - The company is actively advancing its real estate divestiture strategy [1] - The company aims to balance expenditure to maintain stable profits [1] - The growth hormone business currently faces no competition in the market [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.47% on November 19, with Jindike leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Individual Stock Performance - Notable gainers included *ST Sihuan, which rose by 1.15% to a closing price of 2.63, and Teabo Bio, which increased by 0.91% to 77.78 [1] - Significant decliners included Jindike, which fell by 6.60% to 25.03, and Hualan Store, down 5.98% to 22.80 [2] Trading Volume and Value - The trading volume and value for key stocks in the biopharmaceutical sector were highlighted, with Anke Bio recording a volume of 210,100 hands and a transaction value of 218 million [1] - Jindike had a trading volume of 95,600 hands and a transaction value of 237 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 911 million from institutional investors, while retail investors contributed a net inflow of 845 million [2] - The capital flow for individual stocks showed that Changchun High-tech had a net inflow of 8.84 million from institutional investors, while it experienced a net outflow of 10.70 million from speculative funds [3]

Group 1: Computer Industry Investment Strategy - The year 2025 marks the beginning of domestic computing power industrialization, with significant advancements in domestic AI chips and server architecture, enhancing overall computing performance [10] - The gap between Chinese and American large models is narrowing, with expectations of further convergence and potential surpassing in certain areas by 2026 [10] - The software industry is entering an optimal layout window as AI revenue for many companies exceeds 10%, indicating a technological revolution [10] - Investment focus areas include Deep Research, AI programming, multi-modal applications, and industry-specific agents [10] Group 2: Real Estate Industry Investment Strategy - The real estate market is expected to structurally bottom out, with five major opportunities identified, including stabilization of residents' balance sheets and improved housing affordability [12][18] - The policy direction will focus on stabilizing demand and promoting high-quality development, which will benefit real estate companies [18] - Predictions for 2025-2026 include a decline in sales volume and prices, but core cities are expected to stabilize sooner due to healthier supply-demand relationships [18] Group 3: Pharmaceutical Industry Investment Strategy - Chinese pharmaceutical companies are increasingly leading global multi-center clinical trials, with a growing number of new drugs successfully commercialized overseas [15] - The shift from "fast following" to "innovation leading" in drug development positions Chinese companies to redefine the global pharmaceutical landscape [15] - Investment directions include biotech transitioning to biopharma and the revaluation of traditional pharmaceutical companies during their innovation transformation [15]

Core Points - The Shenzhen State-owned Enterprise ESG Index (970055) closed at 1382.09 points, down 0.8%, with a trading volume of 27.288 billion yuan and a turnover rate of 1.05% [1] - Among the index constituents, 15 stocks rose while 35 fell, with Inspur Information leading the gainers at 1.71% and Zhonglai Co., Ltd. leading the decliners at 7.27% [1] Index Constituents - The top ten constituents of the Shenzhen State-owned Enterprise ESG Index include Hikvision, BOE Technology Group, Wuliangye Yibin, Weichai Power, Inspur Information, Yun Aluminum, Shenwan Hongyuan, AVIC Optoelectronics, Changchun High-tech, and China Merchants Shekou [1] - The weights of the top constituents are as follows: Hikvision (10.20%), BOE Technology Group (9.22%), Wuliangye Yibin (8.57%), Weichai Power (7.34%), and Inspur Information (6.49%) [1] Capital Flow - The net outflow of main funds from the index constituents totaled 1.02 billion yuan, while retail investors saw a net inflow of 574 million yuan [1] - Detailed capital flow for specific stocks shows that Zhongtung High-tech had a net inflow of 168 million yuan from main funds, while Inspur Information experienced a net outflow of 74.51 million yuan from main funds [2]

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Group 1 - The report emphasizes the rapid development of China's innovative pharmaceuticals, highlighting that the number of clinical trials has reached a global leading position, with a significant increase in new drug approvals [3][5][7] - Chinese pharmaceutical companies are transitioning from a "fast follower" to an "innovation leader" model, actively engaging in cutting-edge fields such as ADC, bispecific antibodies, and mRNA vaccines, with a notable increase in the number of products in late-stage development [8][11][18] - The report identifies two main investment directions: the transformation of biotech companies into biopharma and the revaluation of traditional pharmaceutical companies during their innovation transition, suggesting specific companies to watch in both categories [3][4] Group 2 - China's integration into the global innovative drug value chain is deepening, with a growing number of global multi-center clinical trials led by Chinese companies, indicating a shift in the global drug development landscape [3][24] - The report notes that the contribution of Chinese companies to global clinical trials has significantly increased, with a projection of 1,903 innovative drug clinical trials registered in China by 2024 [7][24] - The report highlights the increasing competitiveness of Chinese companies in high-potential therapeutic areas, particularly in oncology, metabolic diseases, and autoimmune diseases, with substantial market shares in these segments [18][19] Group 3 - The report discusses the rising trend of BD (business development) transactions involving Chinese assets, with a notable increase in transaction amounts and numbers, indicating China's growing influence in the global pharmaceutical innovation landscape [33][44] - It highlights that the majority of license-out projects are now in early stages, reflecting the international interest in early-stage Chinese innovations, particularly in oncology and metabolic therapies [39][44] - The report points out that major multinational corporations (MNCs) are increasingly seeking next-generation blockbuster products from China to fill revenue gaps due to impending patent expirations [62][66]

Investment Rating - The report does not explicitly state an investment rating for the industry [2][19]. Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 3.29%, outperforming the Wind All A index (-0.47%) and the CSI 300 index (-1.08%) during the week of November 10-14, 2025 [3][8]. - Local governments are actively implementing policies to support innovative drug development, with Chongqing aiming to approve 1-3 new drugs annually by 2027 [3][13]. - Flu activity is on the rise, with the percentage of flu-like illness cases reported in southern provinces reaching 5.5%, higher than the previous week and the same period in 2022 and 2024 [3][13]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 3.29%, with all sub-sectors recovering. The leading sub-sectors included pharmaceutical distribution (5.92%), in vitro diagnostics (5.91%), and raw materials (5.09%) [3][8]. - Notable stock performances included Jindike (61.6%), Renmin Tongtai (61.1%), and Chengda Pharmaceutical (58.3%) with significant gains, while *ST Changyao (-33.6%) and Zhend Medical (-11.3%) faced substantial declines [3][11]. Industry News and Key Company Announcements - On November 14, Chongqing's government announced comprehensive support measures for innovative drug development, including funding for research and expedited ethical review processes [3][13]. - Merck announced a $9.2 billion acquisition of Cidara Therapeutics, expected to close in Q1 2026 [3][13]. - Adicon acquired Crown Bioscience for $204 million, aiming to enhance its integrated service platform [3][13]. - Laika Pharmaceuticals entered an exclusive licensing agreement with Qilu Pharmaceutical for LAE002, with potential payments totaling RMB 25.75 billion [3][14]. - Lyell Immunopharma announced a global licensing agreement for LYL273, with significant milestone payments and royalties [3][15]. - MeiraGTx Holdings entered a strategic collaboration with Eli Lilly for gene therapy projects, with upfront and milestone payments exceeding $400 million [3][15].